We are live on ! Find out more
PI

Pennant Investors Portfolio holdings

AUM $361M
1-Year Est. Return 134.26%
This Fund
S&P 500
This Quarter Est. Return
+19.01%
1 Year Est. Return
+134.26%
3 Year Est. Return
+359.01%
5 Year Est. Return
+289.76%
10 Year Est. Return
–
AUM
$404M
AUM Growth
-$54.4M
Cap. Flow
-$97M
Cap. Flow %
-24.04%
Top 10 Hldgs %
88.07%
Holding
46
New
2
Increased
1
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
ENOV icon
Enovis
ENOV
+$23.9M
2
AR icon
Antero Resources
AR
+$5.31M

Top Sells

Rank Stock Value
1
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$25.2M
2
AMZN icon
Amazon
AMZN
+$8.68M
3
MSFT icon
Microsoft
MSFT
+$6.88M
4
TVTX icon
Travere Therapeutics
TVTX
+$502K

Sector Composition

Rank Sector Weight
1 Technology 20.64%
2 Consumer Discretionary 18.48%
3 Communication Services 15.04%
4 Industrials 12.92%
5 Healthcare 10.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMZN icon
1
Amazon
AMZN
$2.92T
$53.4M 13.23%
296,000
-52,000
-15% -$8.68M
TDG icon
2
TransDigm Group
TDG
$70.2B
$51.7M 12.81%
42,000
– –
MSFT icon
3
Microsoft
MSFT
$3.45T
$47.1M 11.67%
112,000
-17,000
-13% -$6.88M
MU icon
4
Micron Technology
MU
$930B
$36.1M 8.94%
306,000
– –
AR icon
5
Antero Resources
AR
$11.1B
$32.9M 8.14%
1,133,000
+220,000
+24% +$5.31M
ECHO
6
EchoStar
ECHO
$24.4B
$30.7M 7.6%
2,153,209
– –
GOOGL icon
7
Alphabet (Google) Class A
GOOGL
$4.36T
$30M 7.44%
199,000
-176,000
-47% -$25.2M
AAPL icon
8
PUT
Apple
AAPL
$4.54T
$27.4M 6.8%
160,000
-470,000
-75% -$85.5M
ENOV icon
9
Enovis
ENOV
$1.68B
$25M 6.19%
+400,000
New +$23.9M
ODP
10
DELISTED
ODP
ODP
$21.2M 5.26%
400,000
– –
PRM icon
11
Perimeter Solutions
PRM
$4.99B
$17.1M 4.23%
2,300,000
– –
AR icon
12
CALL
Antero Resources
AR
$11.1B
$14.5M 3.59%
500,000
– –
KYNB
13
Kyntra Bio
KYNB
$27.2M
$1.81M 0.45%
30,736
– –
ARQT icon
14
Arcutis Biotherapeutics
ARQT
$3.36B
$1.69M 0.42%
170,900
– –
ALT icon
15
Altimmune
ALT
$552M
$1.12M 0.28%
109,800
– –
FATE icon
16
Fate Therapeutics
FATE
$286M
$1.07M 0.27%
146,100
– –
NRIX icon
17
Nurix Therapeutics
NRIX
$2.41B
$835K 0.21%
56,800
– –
MGNX icon
18
MacroGenics
MGNX
$235M
$645K 0.16%
43,800
– –
IGMS
19
DELISTED
IGM Biosciences
IGMS
$626K 0.16%
64,900
– –
ENTA icon
20
Enanta Pharmaceuticals
ENTA
$366M
$613K 0.15%
35,100
– –
ALLO icon
21
Allogene Therapeutics
ALLO
$649M
$574K 0.14%
128,400
– –
ETNB
22
DELISTED
89bio
ETNB
$518K 0.13%
44,500
– –
ZNTL icon
23
Zentalis Pharmaceuticals
ZNTL
$337M
$511K 0.13%
32,400
– –
RCUS icon
24
Arcus Biosciences
RCUS
$3.55B
$447K 0.11%
23,700
– –
ARCT icon
25
Arcturus Therapeutics
ARCT
$164M
$442K 0.11%
13,100
– –
1
2

Similar funds

BCC
Bridge City Capital Lake Oswego, Oregon $361M AUM 38.29% 1-Year Est. Return
PPG
Peak Planning Group Centennial, Colorado $361M AUM 22.01% 1-Year Est. Return
VWM
VCI Wealth Management St Louis, Missouri $361M AUM 23.02% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return
DAS
Daybright Advisory Services Miami, Florida $361M AUM
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
DF
Donoghue Forlines Boston, Massachusetts $361M AUM 49.41% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return

Pennant Investors's Q1 2024 Portfolio in Review

As of Q1 2024, Pennant Investors held 46 positions worth $404M, down 12% from $458M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Pennant Investors withdrew a net $97M in Q1 2024, closing 1 position and reducing 4 holdings. Its most notable exit was Travere Therapeutics, an estimated $502K position sold in full.

By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Communication Services.

Against the trend, Pennant Investors opened a new position in Enovis worth $25M.

  • Pennant Investors's largest Q1 2024 buy was Enovis: 400,000 shares worth $25M.
  • Pennant Investors added most to Antero Resources in Q1 2024, an estimated $5.31M increase.
  • Pennant Investors's biggest Q1 2024 reduction was Alphabet (Google) Class A, cutting an estimated $25.2M.
  • Pennant Investors fully exited Travere Therapeutics in Q1 2024, selling an estimated $502K.
  • Pennant Investors's ten largest holdings make up 88% of its $404M portfolio in Q1 2024.
  • Pennant Investors opened 2 new positions and closed 1 in Q1 2024.
  • Pennant Investors's portfolio value fell 12% quarter-over-quarter to $404M.

Based on Pennant Investors's 13F filing for Q1 2024, filed 15 May 2024.